Aliskiren: An oral direct renin inhibitor for the treatment of hypertension

Pharmacotherapy

Volumn 29, Issue 2, 2009, Pages 193-212

  Sanoski, Cynthia A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Aliskiren; Hypertension; RAAS; Renin inhibitors; Renin angiotensin Aldosterone system

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ATENOLOL; ATORVASTATIN; CANDESARTAN; CARVEDILOL; CELECOXIB; CIMETIDINE; CYTOCHROME P450; DIGOXIN; DILTIAZEM; ENALAPRIL; ENALKIREN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LISINOPRIL; LOSARTAN; METOPROLOL TARTRATE; MEVINOLIN; PLACEBO; RAMIPRIL; REMIKIREN; VALSARTAN; WARFARIN; ZANKIREN;

ADD ON THERAPY; ANEURYSM RUPTURE; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; BACKACHE; BLOOD PRESSURE MEASUREMENT; CHEST TIGHTNESS; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OUTCOME ASSESSMENT; PERIORBITAL EDEMA; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; WEAKNESS;

ADMINISTRATION, ORAL; AMIDES; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DRUG APPROVAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN; UNITED STATES;

EID: 59949088729     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.2.193     Document Type: Review

References (65)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2008;117: e25-146.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365: 217-23.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289: 2560-72.
4. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007;115: 2761-88.
5. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49: 69-75.
6. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin-converting enzyme inhibitors in cardio vascular disease : the task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25: 1454-70.
7. Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis 2004;47: 105-15.
8. Eisenberg MJ, Gioia LC. Angiotensin II receptor blockers in congestive heart failure. Cardiol Rev 2006;14: 26-34.
9. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin- converting enzyme inhibitors. Prog Cardiovasc Dis 2004;47: 116-30.
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-62.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: 851-60.
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341: 709-17.
13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
14. Brown MJ. Direct renin inhibition: a new way of targeting the renin system. J Renin Angiotensin Aldosterone Syst 2006;7: S7-11.
15. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000;52: 11-34.
16. Azizi M, Menard J. Co mbined blockade of the renin- angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109: 2492-9.
17. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25: 37-46.
18. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32: 387-92.
19. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11: S49-52.
20. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immuno-pharmacol 2003;3: 311-17.
21. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor- induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129: S169-73.
22. Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003;3: 389-94.
23. Batenburg WW, Danser AHJ. The (pro)renin receptor: a new addition to the renin-angiotensin system? Eur J Pharmacol 2008;585;320-4.
24. Burckle C, Bader M. Pro renin and its ancient recepto r. Hypertension 2006;48: 549-51.
25. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents 2003;13: 589-603.
26. Novartis Pharmaceuticals Corporation. Tekturna (aliskiren) package insert. East Hanover, NJ; 2007.
27. O'Brien E. Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Exp Opin Invest Drugs 2006;15: 1269-77.
28. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308: 698-705.
29. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46: 569-76.
30. Wood JM, S chnell C R, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23: 417-26.
31. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368: 1449-56.
32. Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006;62: 690-8.
33. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45: 1125-34.
34. N ussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren ( SPP1 00): comparison with enalapril. Hypertension 2002;39: e1-8.
35. Vaidyanathan S. Aliskiren, a novel oral renin inhibitor, has no interaction with cytoc hrome P45 0 iso enzymes in vitro [abstract]. Basic Clin Pharmacol Toxicol 2005;97(suppl 1): 239.
36. Waldmeier FJ, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35: 1418-28.
37. Azizi M, Menard J, Bissery A, et al. Pharmac o logic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15: 3126-33.
38. Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47: 453-60.
39. Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007;47: 192-200.
40. Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46: 661-75.
41. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patie nts with hypertension. J Am Coll Cardiol 2007;49: 1157-63.
42. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42: 1137-43.
43. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and place bo -like tolerability in hype rte nsive patients. Circulation 2005;111: 1012-18.
44. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blo od pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49: 276-84.
45. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20: 11-20.
46. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370: 221-9.
47. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25: 217-26.
48. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49: 1047-55.
49. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8: 190-8.
50. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358: 2433-46.
51. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the aliskiren left ventricular assessment o f hypertrophy (ALLAY) trial. Presented at the 57th annual scientific session of the American College of Cardiology, Chicago, IL, March 29-April 1, 2008.
52. Pitt B, McMurray JJ, Latini R, et al. Neurohumoral effects of a new oral direct renin inhibitor in stable heart failure: the aliskiren observation of heart failure treatment study (ALOFT) [abstract 2491]. Circulation 2007;116: II549.
53. Novartis Pharmaceutical Corporation. Safety and efficacy of aliskiren in post myocardial infarction patients (ASPIRE). Available from http://www.clinicaltrials.gov/ct/show/NCT00414609. Accessed August 15, 2008.
54. Parving HH, Brenner BM, McMurray JJV, et al. Aliskiren trial in type 2 diabetes using cardio -renal disease endpoints ( ALTITU DE) : rationale and study design. Presented at American Society of Nephrology renal week 2007, San Francisco, CA, October 31-November 5, 2007.
55. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007;21: 780-7.
56. Novartis Pharmaceutical C orp oration. Tekturna HCT ( hydrochlorothiazide and aliskiren) package insert. East Hanover, NJ; 2008.
57. Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007;62: 842-56.
58. Dieterle W, C orynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43: 527-35.
59. Vaidyanathan S, ValenciaJ, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60: 1343-56.
60. Ayalasomayajula S, Tchaloyan S, Yeh CM, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008;24: 717-26.
61. Dieterle W, C orynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmaco- dynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58: 433-6.
62. Vaidyanathan S, Reynolds C, Yeh CM, et. al. The pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with the P-glycoprotein modulators ketoconazole, digoxin, and atorvastatin in healthy subjects [abstract]. Clin Pharmacol Ther 2007;81: S109.
63. Zhao C, Vaidyanathan S, Dieterich HA, Yeh C, Howard D, Dole WP. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract]. Clin Pharmacol Ther 2007;81: S110.
64. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354: 2443-51
65. Drugstore.com. Prescription price checker. Available from http://www.drugstore.com/pharmacy/drugindex/default.asp?aid= 332828&aparam=sespider&trx=3888. Accessed August 14, 2008